Approved for use through 10/31/2002 OMB 0651-0031**
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contribi number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

 Complete If Known

 Application Number
 10/552,065

 Firing Date
 October 5, 2005

 First Named Inventor
 Kai SCHIEMANN et al.

 Group Art Unit
 1614

 Examirer Name
 Christopher R. Stone

 Attorney Docken Number
 MERCK-3074

(use as many sheets as necessary)
Sheet 1 of 4

			U.S. P	ATENT DOCUMENTS	
Examiner Initials *	Cite No.1	U.S. Patent Docume	ent Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A1	2007/0093492		Jiaang et al.	04-2007
	A2	2006/0276650		Schadt et al.	12-2006
	A3	2007/0105871		Schiemann et al.	05-2007
	A4	2001/0044445		Bamaung et al.	11-2001
	A5	7,067,507		Pulley et al.	06-2006
	A6	4,631,343		Beck, James R.	12-1986
	A7	2004/0034083		Stephenson et al.	2-19-2004
	A8	2002/0091116		Zhu et al.	07-2002
	A9	2007/0010531		Schadt et al.	01-2007
	A10	6,150,393	A	Behan et al.	11-21-2000
	A11	6,043,261	A	Hansen Jr. et al.	03-28-2000
	A12	4,146,721	Α	BYK GULDEN LOMBERG	03-27-1979
	A13	3,926,999		Poetsch	12-16-1975
	A14	4,258,047		Gante et al.	03-24-1981

				FOREIGI	N PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (# known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*	
	B1	wo	0132626		Gaster Laramie Mary	05-10-2001		
	B2	wo	2001032627		Baron et al.	10-2001		
	В3	wo	03088958		Maziasz Timothy J	10-30-2003		
	B4	wo	98031227		Schiemann et al.	07-1998		
	B5	wo	2003031435		Schiemann et al.	04-17-2003		

Signature Considered	Examiner Signature		Date Considered	
----------------------	-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chiel Information Officer, U.S. Patrion and Trademark.

Office. Washington, D. 20231, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Mexandria, V.A. 2231-1450.

¹ Unique obtation designation number. ² See attached Kinds of U.S. Patient Documents. ² Enter Office that issued the document, by the two-feter code (WPO Sathada et 33). ³ For Jupanese patient documents, bis indication of the year of the reign of the Empore must proceed the serial necessary to the patient document. ³ Kind of occurrent by the appropriate symbols as indicated on the document under WPO Sathadard ST. 16 if possible. ³ Applicant is to place a check mark here it English in anjaugup Translation is attached. Number refers to English in anjaugup corresponding is attached. Sumber refers to English in anjaugup corresponding in a translation.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Paperwo	rk Redu	ction Act of 1995, no persons ar	e required to respond to a collection o	finformation unless it contains a valid OMB control number		
Substitute	for form 1449A/PTC)		Complete if Known			
				Application Number	10/552,065		
INFO	RMATION	DIS	CLOSURE	Filing Date	October 5, 2005		
STAT	LEMENT B	Y AI	PPLICANT	First Named Inventor	Kai SCHIEMANN et al.		
				Group Art Unit	1614		
	(use as many she	ets as	necessary)	Examiner Name	Christopher R. Stone		
Sheet	2	of	4	Attorney Docket Number	MERCK-3074		

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Patent Door	ument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			

				FOREIG	N PATENT DOCUMENTS			
			Foreign Patent Docum	ent		Date of Publication	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
	B6	WO	01/29008	A	ARENA PHARMACEUTICALS INC.	04-26-2001		A11
	B7	WO	96/33175	A	SEARLE & CO	10-24-1996		A12
	B8	DE	2141125	А	BYK-GULDEN LOMBERG GMBH	02-24-1972		
	B9	wo	03/099793	A	TAKEDA LTD	12-04-2003		
	B10	wo	2004/024705	Α	TAKEDA LTD.	03-25-2004		
	B11	wo	2004/037248	A	CAREX SA	05-06-2004		
	B12	DE	2201889		Merck Patent GmbH	07-19-1973		A13
	B13	DE	2258033		Merck Patent GmbH	05-30-1974		
	B14	DE	2906252		Merck Patent GmbH	08-28-1980		A14

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique criation designation number. ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code of WIPO Standard ST31, ² For Japanese patent documents, the iniciation of the year of the reign of the Empore must proceed the sear in long patent document. ³ Kind of cocument by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ³ Applicant is to place a check mark here if English impages Translations is attached. Number refers to English in aquase corresponding family werefine.

urden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark.

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute fe	or form 1449A/PTC)			Complete if Known
INICOL	MATION	DIO	OL OOUBE	Application Number	10/552,065
			CLOSURE	Filing Date	October 5, 2005
SIAII	EMENI B	ΥA	PPLICANT	First Named Inventor	Kai SCHIEMANN et al.
				Group Art Unit	1614
(4	use as many she	ets as	necessary)	Examiner Name	Christopher R. Stone
Sheet	3	of	4	Attorney Docket Number	MERCK-3074

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, oity and/or country where published	T2
	C1	DATABASE BEILSTEIN 'ONLINE! BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, JUNE 27, 1988, XP002283830.	
	C2	Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.	
	СЗ	Premenstrual syndrome-Womens health and Medical Information in Medicinenet.com", http://www.medicinenet.com/premenstrual_syndrome/page5.htm, accessed September 19, 2007.	
	C4	Amyotrophic Lateral sclerosis information page: National Institute of Neurological Disorders and Stroke (NINDS)*, http://www.ninds.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm, accessed September 19, 2007.	
		Obsessive-compulsive behaviors and disorders: symptoms, treatment, and support*, http://www.helpguide.org/mental/obsessive_compulsive_disorder_ocd.htm, accessed September 19, 2007.	
	C6	Journal of Clinical Psychiatry, 1999, 60, 1-8.	
	C7	Crow, S. Expert Opinion on Investigational Drugs, 1997, 6(4), 427-36.	
	C8	Ross et al., Expert Opinion on Therapeutic Patents, 2003, 13(10), 1491-99.	
	С9	TAKEHITO OCHI ET AL.: "FR143166 ATTENUATES SPINAL PAIN TRANSMISSION THROUGH ACTIVATION OF THE SEROTOMIS SYSTEM FURDEAN JOURNAL OF PHARMACOLOGY, Bd. 452, 2002, Pages 319-324, VP002284473, The Entire Document.	
	C10	YOSHIKO SUZUKI ET AL: "IN VITO AND IN VIVO PHARMACOLOGICAL PROFILE OF 4-(4- FLUOROBENZYLIDEN)-1-(2-76-(4-FLUOROP HEWL)-11+-PYRAZOL-4-YLIETHYL) PIPERIDINE (NRAD161)* LIFE SCIENCES, Bd. 71, 2002, pages 2603-2615, XPO02284474, The Entire Document.	
		KATRITZKY ET AL: "1,3-DIPOLAR CYCLOADDITIONS OF ELECTRON-RICH BENZOTRIAZOL-1- YLPROPENES" J. HETEROCYCLIC CHEM., Bd. 33, 1996, Pages 1637-1646, XP002284475, Figure 26, Pages. 1640.	
		PEREZ ET AL: "AN EASY METHOD FOR THE N-ALKYLATION OF AMIDES, CARBAMATES, UREAS AND AZOLES" HETEROCYCLES, Bd. 60, Nr. 1, 25 November 2002, Pages 167-175, XP002284476, Figures 10,11 and 12, Pages 168 and 173.	

Examiner	Date	
	Considered	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any promoting the amount of time you are required to complete this form should be sent to the Chief Information Clinice, U.S. Patient and Trademark Office. Washington, D.C. 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner of Patients, P.O. 50x 1450, Meanning I.W. 2021.31-450.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute f	or form 1449A/PTC)		Complete if Known		
INITO	NA A TION	DIO.	01.001105	Application Number	10/552,065	
			CLOSURE	Filing Date	October 5, 2005	
STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Kai SCHIEMANN et al.	
				Group Art Unit	1614	
(use as many she	ets as	necessary)	Examiner Name	Christopher R. Stone	
Sheet	4	of	4	Attorney Docket Number	MERCK-3074	

ook, magazine, where published
CHEM.,
O, US; 1960, OF 1- NO. ; ISSN: 0044-
URT-MAIN, CAS-RN; 46.
GLUCOSE
3C NMR 993, PAGES
URT-MAIN, RATENKO ET
993, UR

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patents and Tademan.

- Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1650, Researding, VA 2231-31450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.